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Background. A proportion of patients with tuberculosis diagnosed by sputum culture during screening before
antiretroviral therapy (ART) have false-negative Xpert MTB/RIF assay results (Xpert-negative tuberculosis). We
determined the characteristics and early ART program outcomes of such patients.
Methods. Adult patients who enrolled in a South African township ART service were systematically screened for
pulmonary tuberculosis regardless of symptoms by testing paired sputum samples with Xpert MTB/RIF and liquid
culture. The ART service provided follow-up for all patients, and early (90-day) programmatic outcomes were
determined.
Results. Among 602 patients screened, 523 had $1 Xpert and culture result, yielding 89 culture-positive
tuberculosis diagnoses. Of these, 37 (42%) of the patients with tuberculosis were Xpert-negative when a single
sputum sample was tested, compared with 25 (28%) when 2 samples were tested. Compared with patients with
Xpert-positive tuberculosis, those with Xpert-negative tuberculosis (using either deﬁnition) had substantially higher
CD4 cell counts, lower plasma viral loads, higher hemoglobin concentrations, and higher body mass index. Their
tuberculosis was also less advanced, with a lower frequency of prolonged cough ($2 weeks), less extensive
radiographic abnormalities, and a lower frequency of detectable lipoarabinomannan antigenuria and
mycobacteriuria. Xpert-negative cases were all sputum smear negative with prolonged time to culture positivity
(median, 21 days). Despite greater delays in starting tuberculosis treatment, Xpert-negative patients were less likely
to die during follow-up.
Conclusions. Compared to patients with Xpert-positive tuberculosis diagnosed during pre-ART screening,
Xpert-negative cases had less advanced immunosuppression and less advanced tuberculosis and did not have
adverse outcomes despite substantial delays in starting tuberculosis treatment.
The Xpert MTB/RIF assay represents a major break-
through in diagnostics for tuberculosis [1–3]. This
rapid molecular assay can be used close to the point of
care by operators with minimal technical expertise,
enabling diagnosis of tuberculosis and simultaneous
assessment of rifampicin resistance within 2 hours
when testing unprocessed sputum samples or speci-
mens from extrapulmonary sites [1]. Testing a single
sputum sample detects 98%–100% of smear-positive
pulmonary tuberculosis and between 57% and 83%
of sputum smear-negative disease in adults presen-
ting with suspected tuberculosis [1]. The assay was
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cember 2010 as a replacement for sputum smear microscopy
in resource-limited settings, especially in clinical populations
with high rates of multidrug-resistant tuberculosis or human
immunodeﬁciency virus (HIV)–associated tuberculosis [4].
Some countries such as South Africa have embarked on
national implementation of the Xpert MTB/RIF assay. How-
ever, much research is needed to guide this process and to
address the many operational questions that are emerging.
A ni m p o r t a n ti s s u et h a th a sn o ty e tb e e na d d r e s s e di st h e
implication of false-negative Xpert MTB/RIF results (hereaf-
ter referred to as ‘‘Xpert-negative tuberculosis’’). Although
much attention has focused on the challenges of sputum
smear-negative HIV-associated tuberculosis [5], we now need
to characterize this new subpopulation of patients with Xpert-
negative tuberculosis.
We reported elsewhere on the utility of the Xpert MTB/RIF
assay for screening patients for HIV-associated tuberculosis
before starting antiretroviral therapy (ART) in a South African
township [6]. Although the assay increased case ﬁnding by 45%
compared with sputum smear microscopy, sputum samples
from more than one-quarter of culture-positive cases never-
theless tested Xpert-negative even when paired sputum sam-
ples were tested [6]. In this study, we report on the clinical,
hematological, microbiological, and radiological character-
istics of patients with Xpert-negative tuberculosis diagnosed
in this clinical setting, and we relate Xpert status to sub-
sequent clinical and programmatic outcomes. To broaden the
applicability of these data to settings where only 1 test is
performed, we analyzed data in 2 ways, ﬁrst deﬁning patients
as Xpert-negative by a negative test on a single sputum
sample and then by negative tests on 2 samples. These data
will help to shape policies regarding screening algorithms for
HIV-associated tuberculosis.
METHODS
The ART service in Gugulethu township, Cape Town, South
Africa, has been described in detail elsewhere, and the major
burden of tuberculosis in these patients’ population has been
characterized in detail [7–9]. The current cohort of patients were
recruited between 12 March 2010 and 20th April 2011, and the
cases of some of these patients have been described elsewhere
[6,10].ConsecutiveeligibleHIV-infectedpatientswererecruited
from among patients newly referred to the clinic for ART. Study
eligibility criteria included age .18 years, being ART naive and
having no current tuberculosis diagnosis. All participants pro-
vided written informed consent and the study was approved by
the research ethics committees of the University of Cape Town,
Cape Town, South Africa, and the London School of Hygiene
and Tropical Medicine, London, United Kingdom.
At their ﬁrst visit to the clinic, patients were prospecti-
vely recruited, clinically characterized and clinically staged
according to WHO criteria [11]. They were then screened
for tuberculosis and underwent routine baseline laboratory in-
vestigations. Demographic details were recorded, and a stan-
dardized symptom-screening questionnaire (which included the
WHO symptom screen for HIV-associated tuberculosis [12])
was completed. Two sputum samples were requested from
each patient; a spot specimen was ﬁrst obtained, followed
by a second that was induced using nebulized 3% hypertonic
saline. If necessary, both specimens were induced. Urine sam-
ples were also collected and stored at 220C. Blood CD4 cell
counts and plasma viral load were measured for all patients
with routine laboratory services. Chest radiographs were
obtained and analyzed by an experienced reader certiﬁed in
the use of the chest radiograph reading and recording system
[13, 14].
Laboratory Procedures
Sputum specimens were processed using standardized pro-
tocols and quality assurance procedures by a centralized
accredited laboratory, which has previously participated
in international evaluations of the Xpert MTB/RIF assay
conducted by the Foundation for Innovative New Diag-
nostics (FIND), Geneva, Switzerland [2, 3]. Samples were
decontaminated with N-acetyl-L-cysteine and sodium hy-
droxide and concentrated by centrifugation. Smears pre-
pared from the sputum pellets were stained with auramine
O ﬂuorescent stain for ﬂuorescence microscopy, and equal
volumes of the remaining pellet were tested by liquid culture
and the Xpert MTB/RIF assay. All smears graded as scanty,
11,2 1,or3 1 were deﬁned as ‘‘smear positive.’’ Culture was
performed using mycobacterial growth indicator tubes
(MGIT; Becton Dickinson), which were incubated for up
to 6 weeks. Cultures positive for acid-fast bacilli were iden-
tiﬁed as the Mycobacterium tuberculosis complex using
the MTBDRplus assay (Hain Lifesciences). Xpert MTB/RIF
assays were carried out according to the manufacturer’s in-
structions. The results of all tests were read by technologists
blinded to the outcomes of the other assays. To assess pos-
sible culture contamination as a cause of positive cultures
that arose from sputum samples that tested Xpert-negative,
isolates underwent molecular typing using mycobacterial
interspersed repetitive-unit variable-number tandem repeat
(MIRU-VNTR) analysis [15].
Frozen urine samples were thawed and analyzed for the
presence of lipoarabinomannan (LAM) using the commer-
cially available Clearview TB-ELISA (Alere), with strict ad-
herence to the manufacturer’s instructions. The thawed urine
samples (2.0 mL) were also concentrated by centrifugation,
resuspended in 0.75 mL of phosphate buffer, and then tested
1072 d CID 2012:54 (15 April) d Lawn et alusing the Xpert MTB/RIF assay according to the manu-
facturer’s instructions.
Patient Outcomes
Patients were followed up by the routine ART service, and
patients with a diagnosis of tuberculosis (including those
diagnosed by Xpert MTB/RIF) were referred to tuberculosis
clinics within the township for treatment. ART service pa-
tient records were reviewed to determine clinical outcomes.
A record was made of the number of patients who underwent
tuberculosis treatment and ART and when the treatment was
initiated. Program losses due to death, follow-up or transfer
were also ascertained. The clinical courses of patients who
had a negative symptom screen at baseline were also re-
viewed to determine whether they developed symptoms
before starting tuberculosis treatment.
Definitions and Analysis
Patients were deﬁned as having tuberculosis if M. tuberculosis
was cultured from $1 sputum sample. Patients with tuber-
culosis were then categorized in 2 different ways based on
the analysis of Xpert MTB/RIF results from only the ﬁrst
sputum sample or from both samples. In the latter analysis,
patients were classiﬁed as Xpert-positive if either or both
samples tested positive and Xpert-negative if both tests
were negative. Patients were characterized using simple
descriptive statistics, and the sensitivity of the Xpert assay
was calculated for patients stratiﬁed by CD4 cell counts and
sputum smear status. Characteristics and 30- and 90-day
outcomes of patients with Xpert-positive or Xpert-negative
tuberculosis were compared using the Wilcoxon rank-sum
test, Student t test, and v
2 and Fisher’s exact tests, as ap-
propriate. Logistic regression analysis was used to identify
factors independently associated with Xpert-negative dis-
ease. All statistical tests were 2 sided at a5 .05.
RESULTS
Tuberculosis Diagnoses
Of 604 consecutive patients who were eligible and invited,
602 agreed to participate. Sputum samples were obtained
from 542 (90.0%) patients, and culture and Xpert MTB/RIF
results were available from $1 sputum sample for 523
patients (Figure 1). M. tuberculosis was cultured from at
least 1 sample from 89 patients, which represented a 17.0%
prevalence (95% conﬁdence interval, 13.9–20.5) of culture-
proven pulmonary tuberculosis among these patients.
Twenty-four (27.0%) cases were sputum smear positive, and
65 (73%) were smear negative.
Of the cases of culture-conﬁrmed tuberculosis (n 5 89),
37 (41.6%) were Xpert-negative and 52 (58.4%) were Xpert-
positive based on the results of the ﬁrst sputum sample
(Figure 1). Basedon the results of 2 samples, 25 (28.1%) were
Xpert-negative (both samples negative), and 64 (71.9%)
were Xpert-positive (1 or 2 samples positive).
Patients with a diagnosis of tuberculosis had a median age
of 33.4 years (interquartile range [IQR], 28.3–40.4); 62% were
female, the median body mass index was 21.2 kg/m
2 (IQR,
19.2–25.0) and 21.4% of cases had retreatment disease. The
median CD4 cell count was 131 cells/lL (IQR, 55–204), median
plasma viral load was 4.8 log10 copies/mL (IQR, 4.4–5.3) and
47% of cases had a history of WHO stage 3 or 4 (AIDS) disease.
Although a positive WHO symptom screen (any cough, fever,
weight loss or night sweats) was recorded in a majority
(82.0%) of patients, only 24.7% had cough of $2 weeks
duration.
Characteristics of Patients With Xpert-Negative Tuberculosis
Patients with Xpert-positive or Xpert-negative tuberculosis
were deﬁned in 2 ways, initially using the ﬁrst sputum sample
result and then using both sputum sample results. Regardless
of the way patients were deﬁned, there were notable differ-
ences between Xpert-negative and Xpert-positive patients
(Table 1). Xpert-negative patients had less advanced HIV in-
fection with higher CD4 cell counts and lower plasma viral
loads. They were also far less likely to report a cough of
$2 weeks duration and they had a higher median body mass
index, higher median hemoglobin concentration, and a lower
Figure 1. Flow diagram showing numbers of patients studied,
tuberculosis cases diagnosed and numbers of cases diagnosed by Xpert
MTB/RIF testing of 1 or 2 sputum samples.
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characteristics, 3 variables remained strongly associated with
Xpert status in the ﬁnal model (Table 2). Xpert-negative pati-
ents were more likely to have higher CD4 cell counts, a lower
plasma viral load, and a lower blood neutrophil count.
In view of the strong association with CD4 cell count, we
next examined how the sensitivity of Xpert MTB/RIF varied
across a range of CD4 cell count strata (Figure 2). This con-
ﬁrmed that the Xpert MTB/RIF assay had the highest sensiti-
vity among those with the lowest CD4 cell counts with testing
of either 1 (Figure 2A)o r2( Figure 2B) sputum samples.
Results of Other Diagnostic Tests
We next explored the relationship between sputum Xpert status
and the results of other tuberculosis investigations (Table 3).
None of the Xpert-negative cases were sputum smear positive,
whereas more than one-third of the Xpert-positive cases were
smear positive. Moreover, the median time to positivity for
detection of growth of M. tuberculosis in automated liquid cul-
ture was substantially longer for patients with Xpert-negative
tuberculosis than for those withXpert-positivetuberculosis. The
proportions of patients withdetectableLAM antigenuria and M.
tuberculosis bacteriuria detected using the Xpert MTB/RIF assay
Table 1. Characteristics of Patients (n 5 89) With Tuberculosis Diagnosed During Screening Before Antiretroviral Therapy and
Stratified According to Whether Patients Had Positive or Negative Xpert MTB/RIF Results With Testing of 1 or 2 Sputum Samples
Results of Xpert Test (1 Sample) Results of Xpert Test (2 Samples)
Variable
Negative
(n 5 37)
Positive
(n 5 52) P
Negative
(n 5 25)
Positive
(n 5 64) P
Patient characteristics
Age, median (IQR), years 34.3 (28.6–40.4) 32.3 (27.5–39.4) .566 32.1 (28.7–38.0) 33.5 (26.8–40.7) .927
Female, No. (%) 22 (59.5) 33 (63.5) .702 16 (64.0) 39 (60.9) .789
BMI, median (IQR), kg/m
2 22.1 (20.4–27.2) 20.8 (18.8–23.0) .049 22.1 (20.6–28.5) 21.0 (18.8–23.8) .037
History of tuberculosis, No. (%) 10 (27.0) 9 (17.3) .270 5 (20.0) 14 (21.9) .846
Blood test results
a
Hemoglobin, g/dL 11.6 (10.3–12.8) 9.5 (8.1–11.6) .002 11.6 (10.4–13.1) 10.1 (8.5–11.7) .029
White blood cell
count, 3 10
9 cells/L
5.7 (4.1–6.7) 5.7 (4.9–9.7) .230 5.5 (4.1–6.5) 5.7 (4.9–8.7) .285
Absolute neutrophil
count, 3 10
9 cells/L
2.9 (2.0–4.1) 3.8 (2.6–7.4) .008 2.9 (2.0–3.9) 3.6 (2.5–6.5) .022
Absolute lymphocyte
count, 3 10
9 cells/L
1.8 (1.3–2.4) 1.4 (0.7–1.8) .011 1.8 (1.4–2.4) 1.4 (0.7–1.9) .021
ALT, IU/L 23 (15–32) 21.5 (14–44) .765 20 (14–31) 23 (14–40) .319
Platelets, 3 10
9 cells/L 272 (209–324) 328.5 (220–419) .128 273.5 (240.5–314.5) 328 (210–419) .367
CD4 cell count, median,
cells/lL
183 (112–213) 100 (35–186) .020 189 (137–215) 106 (37–185) .006
CD4 cell count, cells/lL
b .058 .012
,50 5 (13.5) 15 (29.4) 3 (12.0) 17 (27.0)
50–99 4 (10.8) 10 (19.6) 2 (8.0) 12 (19.1)
100–149 6 (16.2) 11 (21.6) 2 (8.0) 15 (23.8)
150–199 9 (24.3) 4 (7.8) 7 (28.0) 6 (9.5)
$200 13 (35.1) 11 (21.6) 11 (44.0) 13 (20.6)
Log viral load, median (IQR),
copies/mL
b
4.7 (4.4–5.1) 4.9 (4.7–5.4) .033 4.4 (4.2–4.7) 5.1 (4.7–5.5) <.001
WHO stage at enrollment, No. (%) .529 .924
1 or 2 21 (56.8) 26 (50.0) 13 (52.0) 34 (53.1)
3 or 4 16 (43.2) 26 (50.0) 12 (48.0) 30 (46.9)
Symptoms
Any cough, fever, night sweats,
or weight loss ($1 symptom)
26 (70.3) 47 (90.4) .015 18 (72.0) 55 (85.9) .124
Current cough $2 weeks 5 (13.5) 17 (32.7) .039 2 (8.0) 20 (31.3) .028
Blood test results are all median (interquartile range) values except for the CD4 categories, which are numbers (%). P values of ,.05 have been indicated in bold.
Abbreviations: ALT, alanine aminotransferase; BMI, body mass index; IQR, interquartile range; WHO, World Health Organization.
a Blood test results were available for 85 patients.
b CD4 cell counts and viral loads were available for 88 patients.
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tuberculosis (Table 3).
After comparing pulmonary radiographic appearances in
the 2 groups, we observed that smaller proportions of patients
with Xpert-negative tuberculosis had hilar and mediastinal
lymphadenopathy or pleural abnormalities, and these pa-
tients also had a lower median number of radiographic zones
affected by parenchymal abnormalities (Table 3). However,
there was no statistical evidence to support these trends.
Patient Outcomes
We next compared the early ART program outcomes of patients
with Xpert-positive and Xpert-negative tuberculosis, ascertaining
outcomes after 30 and 90 days from the time of program en-
rollment when the tuberculosis screening was done (Table 4).
Although the timing of ART initiation did not differ between
the 2 groups, Xpert-negative patients were much less likely
than Xpert-positive cases to start tuberculosis treatment
within 30 days of follow-up and were more likely to start ART
before tuberculosis treatment. However, although the median
time to starting tuberculosis treatment was much longer for
the Xpert-negative compared with the Xpert-positive group
(32 vs 9 days, respectively; P , .001), Xpert-negative patients
did not have adverse outcomes. Of the 6 deaths that occurred,
all were in the Xpert-positive group (Table 4). Similar pro-
portions in the 2 groups were lost to follow-up.
Table 2. Univariate and Multivariate Analysis Using Logistic Regression Showing Association Between Patient Characteristics and
Risk of Xpert-Negative Tuberculosis Among Patients With Culture-Positive Disease for Whom Complete Data Were Available (n 5 85)
Risk Factor Crude Odds Ratio 95% CI P Adjusted Odds Ratio 95% CI P
Age, years
#30 1.0 .. . ..
.30 1.11 .42–2.98 .831 .. .
Sex
Male 1.0 .. . ..
Female 1.14 .44–2.97 .788 .. .
Body mass index, kg/m
2
,18 1.0 .. 1.0 ..
18–25 4.62 .55–38.65 .079 2.06 .18–23.98 .458
.25 8.31 .91–75.73 4.15 .31–55.41
CD4, cells/lL
,150 1.0 . 1.0 ..
$150 5.95 2.14–16.61 .001 4.54 1.17–17.72 .023
Viral load, log copies/mL
$4.5 1.0 .. 1.0 ..
,4.5 6.02 2.16–16.73 .001 6.42 1.56–26.44 .007
Hemoglobin, g/dL
,11 1.0 .. . ..
$11 3.08 1.14–8.31 .022 1.40 .31–6.35 .662
Absolute neutrophil count, 3 10
9 cells/L
$3.5 1.0 .. 1.0 ..
,3.5 2.1 .82–5.92 .109 4.87 1.26–18.89 .016
Absolute lymphocyte count, 3 10
9 cells/L
,1.5 1.0 .. 1.0 ..
$1.5 1.96 .75–5.17 .167 1.20 .31–4.56 .794
Previous tuberculosis treatment
No 1.0 .. . ..
Yes 1.12 .36–3.52 .845 .. .
WHO symptom screen
Positive 1.0 .. . ..
Negative 2.38 .77–7.30 .136 1.38 .26–7.16 .703
Cough $2 weeks
Yes 1.0 .. 1.0 ..
No 5.23 1.12–24.35 .014 3.53 .60–20.91 .135
Abbreviations: CI, conﬁdence interval; WHO, World Health Organization.
Xpert-Negative Tuberculosis d CID 2012:54 (15 April) d 1075Follow-up of Asymptomatic Patients and Strain Typing
Diagnoses of tuberculosis in asymptomatic individuals that
were obtained using liquid culture could arise erroneously
from laboratory contamination, so we determined the clinical
course for such patients. Although 16 patients (18.0%) had
a negative symptom screen at baseline, 12 (75%) of these
developed tuberculosis symptoms during the ﬁrst 8 weeks of
follow-up and 4 (all Xpert-negative) remained asymptomatic
until initiation of tuberculosis treatment. Two of these pa-
tients had abnormal chest radiographs with clearly discernible
parenchymal opacities. Of the remainder, 1 patient had 2
positive cultures, with the shortest time to positivity being
15 days, and the remaining patient had a single positive cul-
ture at 28 days. MIRU-VNTR strain typing of isolates from
all patients (n 5 9) with culture-positive Xpert-negative
tuberculosis in whom there were paired M. tuberculosis iso-
lates revealed identical banding patterns within each pair.
DISCUSSION
Tuberculosis is a leading cause of morbidity, mortality
and nosocomial disease transmission in ART programs in
sub-Saharan Africa [8, 16–19]. The Xpert MTB/RIF assay
represents a major step forward in screening for tuberculosis
in this setting, greatly increasing case ﬁnding compared with
smear microscopy [6]. Nevertheless, in the present study, 42%
of culture-positive cases tested Xpert-negative on the ﬁrst
sputum sample and 28% of cases tested Xpert-negative on 2
samples. Careful comparison of patients with Xpert-positive
tuberculosis showed that those with Xpert-negative tuber-
culosis (deﬁned either by 1 or by 2 negative tests) had less
advanced HIV-associated immunodeﬁciency and less ad-
vanced tuberculosis disease. In addition, despite much
greater delays in starting tuberculosis treatment, patients
with Xpert-negative tuberculosis did not have inferior
early ART program outcomes and were less likely to die.
Thus, the early clinical consequences of the false-negative
Xpert tests were not grave, potentially affording time for
reinvestigation.
Not only did patients with Xpert-negative tuberculosis have
less advanced immunodeﬁciency, but they also had better
prognostic indices, including a higher median body mass in-
dex and higher hemoglobin concentrations. These ﬁndings
were robust whether Xpert-negative tuberculosis was deﬁned
based on 1 or 2 negative tests. Higher CD4 cell counts, lower
plasma viral load and lower blood neutrophil counts were
each strong independent predictors of negative Xpert results.
Thus, although the Xpert assay missed a proportion of tu-
berculosis diagnoses, these were typically in patients with less
advanced immunodeﬁciency. The reason underlying the
higher neutrophil counts in those with Xpert-positive tuber-
culosis is unclear, possibly reﬂecting greater systemic im-
mune activation or copathology, but there is also increasing
evidence for an important role of neutrophils in the host
inﬂammatory response to M. tuberculosis [20].
Other investigations for tuberculosis all strongly suggested
that patients with Xpert-negative tuberculosis had a lower
mycobacterial burden and less advanced tuberculosis disease.
All these cases were smear-negative, the median time to
culture positivity was prolonged, and detection of the LAM
antigen and M. tuberculosis in urine samples was infrequent,
suggesting a low frequency of disseminated tuberculosis [21].
Pulmonary radiographic ﬁndings correlate poorly with myco-
bacterial burden in immunocompromised patients because ab-
normalities are attenuated by the diminished host inﬂammatory
response. However, a trend of less extensive radiographic ab-
normalities was observed in those with Xpert-negative disease.
Collectively, theresults ofthese diagnostic testsand the favorable
prognostic features all suggest that Xpert-negative patients have
Figure 2. Sensitivity (with 95% confidence intervals) of Xpert MTB/RIF
for diagnosing human immunodeficiency virus–associated tuberculosis
during screening of patients before antiretroviral therapy, stratified by
CD4 cell count and sputum smear status. Results displayed are from
screening with 1 (A)o r2( B) Xpert tests.
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and HIV disease.
The analytic limit of detection (95% sensitivity for detection)
of the Xpert MTB/RIF assay has been deﬁned in laboratory
experiments as 131 colony-forming units (CFU)/mL of sputum
[22]. This compares with a threshold of approximately
10 000 CFU/mL for detection by smear microscopy. Thus, the
ﬁnding of Xpert-negative culture-positive disease deﬁnes
a subgroup of patients with very low concentrations of M.
tuberculosis in sputum. These patients are therefore likely to
have a lower tuberculosis transmission risk compared with
Xpert-positive cases. Three groups of patients might be deﬁned
as being broadly associated with incrementally lower myco-
bacterial load: those with culture-positive Xpert-positive
smear-positive tuberculosis, those with culture-positive
Xpert-positive smear-negative tuberculosis, and those with
culture-positive Xpert-negative smear-negative tuberculosis,
with the third category deﬁning Xpert-negative disease.
The natural history of HIV progression and CD4 cell count
decline is typically associated with increasing extrapulmonary
tuberculosis, diminishing frequency of pulmonary cavitation
and lower bacillary load in sputum samples [20]. However, we
studied a very homogeneous population in which advanced
immunodeﬁciency was universal and pulmonary cavitation was
rare. This may partly explain the somewhat counterintuitive
ﬁnding that theXpert MTB/RIF assay had the greatestsensitivity
among patients with the lowest CD4 cell counts. These patients
may have unchecked mycobacterial replication, leading to
higher concentrations of organisms in sputum. This is also
suggested by a similar trend in the sensitivity of smear micros-
copy in this patient population [10].
Although patients with Xpert-negative tuberculosis had
much longer delays in receiving tuberculosis treatment, their
prognosis was not adversely affected, which was most likely
due to their better prognostic characteristics. Furthermore,
patients in this study with Xpert-negative tuberculosis had
the diagnostic ‘‘safety net’’ of sputum cultures, which ulti-
mately revealed their diagnoses and resulted in the initia-
tion of treatment. It is not known whether these cases would
have been diagnosed and what their outcomes would have
been in the absence of additional cultures. If the Xpert MTB/
RIF assay were to be used for pre-ART routine tuberculosis
screening in this setting, it would miss tuberculosis diag-
noses in a proportion of cases with a low mortality risk and
with a low risk of nosocomial tuberculosis transmission.
Subsequent progression of symptoms during follow-up of
such patients may alert healthcare workers to the need for
repeated diagnostic screening, which might include serial
screening with Xpert MTB/RIF.
Patients with HIV-associated tuberculosis and very low CD4
cell counts have a high mortality risk, yet these are the very
patients in whom establishing a tuberculosis diagnosis is often
the most challenging and slow [23]. With the low sensitivity of
diagnostic tools in resource-limited settings, it has been sug-
gested that the use of empiric tuberculosis treatment in pa-
tients with very advanced immunodeﬁciency and a high
tuberculosis risk might be an effective strategy to reduce the
mortality risk [24]. Randomized controlled trials are being
Table 3. Results of Microbiological and Radiological Investigations for Tuberculosis Among All Patients With Tuberculosis and Those
With Xpert-Negative or Xpert-Positive Tuberculosis, as Defined by Results From 2 Sputum Samples
Patients With Tuberculosis
Results of Investigation All Patients (n 5 89) Xpert-Negative (n 5 25) Xpert-Positive (n 5 64) P
Microbiological ﬁndings
Smear positive 24/89 (27.0) 0/25 (0) 24/64 (37.5) ,.001
Time to culture positivity, median (IQR), d 16 (11–21) 21 (17–25) 13.5 (10–18) ,.001
Urine LAM ELISA-positive 23/84 (27.4) 2/25 (8.0) 21/59 (35.6) .014
Urine Xpert-positive 17/85 (20.0) 2/25 (8.0) 15/60 (25.0) .084
Chest radiographic ﬁndings
a
Any abnormality 64/86 (74.4) 17/24 (70.8) 47/62 (75.8) .783
Hilar or mediastinal lymphadenopathy 25/86 (29.1) 4/24 (16.7) 21/62 (33.9) .185
Pleural abnormality 17/86 (19.7) 2/24 (8.3) 15/62 (24.2) .134
Volume loss 12/86 (13.9) 3/24 (12.5) 9/62 (14.5) 1.00
Cavitation 2/86 (2.3) 0/24 (0) 2/62 (3.2) 1.00
Parenchymal abnormality 60/86 (69.8) 17/24 (70.8) 43/62 (69.4) 1.00
Parenchymal abnormality, median No. (%) of zones 3 (1.5–5) 2 (1–4) 3 (2–5) .199
Abbreviations: ELISA, enzyme-linked immunosorbent assay; IQR, interquartile range; LAM, lipoarabinomannan.
a Chest radiographs were obtained from 86 patients. All values are proportions (%) unless otherwise stated.
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However, we found that the Xpert MTB/RIF assay had
the highest sensitivity among patients with the lowest CD4
cell counts, with tests on 2 samples detecting 85% of
sputum culture-positive disease among those with CD4 cell
counts ,100 cells/lL. Thus, the rationale for empiric treat-
ment may be somewhat diminished in settings where Xpert
MTB/RIF becomes available. In ART programs in sub-
Saharan Africa where tuberculosis is a major cause of death
[16], high early mortality may be effectively reduced by using
the assay as a screening tool.
This is the ﬁrst study to report on the characteristics and early
outcomes of patients with Xpert-negative tuberculosis. The
strengths of this study include the careful characterization of
patients with tuberculosis diagnosed during the screening of
unselected consecutive patients, analyses based on the testing
of 1 and 2 sputum samples and comparison with numerous
other tuberculosis diagnostics. Outcomes of ART program los-
ses were also carefully ascertained in this cohort [25], yet deaths
among those lost to follow-up cannot be deﬁnitively excluded.
Weaknesses include the fact that it is not known what the
outcomes of patients with Xpert-negative tuberculosis would
have been in the absence of sputum cultures. It is impossible to
deﬁnitively exclude any cases of culture contamination, yet most
patients with culture-positive disease who were asymptomatic
rapidlydeveloped symptoms during follow-up, and there was
no evidence to suggest contamination based on the molec-
ular typing of paired isolates. The data from the present
study should not be extrapolated to clinical populations of
symptomatic patients with suspected tuberculosis attending
tuberculosis clinics, because Xpert-negative patients in this
setting may have different characteristics.
In conclusion, the Xpert MTB/RIF assay missed 28%–42% of
culture-positive tuberculosis diagnoses (depending on the
number of samples tested) during the pre-ART screening of
patients regardless of symptoms. Any adverse consequences of
missed or delayed diagnoses in patients with Xpert-negative
tuberculosis, however, were offset by the fact that these patients
were less immunocompromised, had less advanced tuberculosis
disease, had a low mortality risk and were likely to have a lower
tuberculosis transmission risk. Good short-term prognosis af-
fords time for further investigation of such patients.
Table 4. Early Antiretroviral Therapy Program Outcomes in all Patients With Tuberculosis and Those With Xpert-Negative and Xpert-
Positive Tuberculosis, as Defined by Results From 2 Sputum Samples
Patients With Tuberculosis
Outcome
All Patients
(n 5 89)
Xpert-Negative
(n 5 25)
Xpert-Positive
(n 5 64) P
30-day follow-up
Started ART 25 (28.1) 7 (28.0) 18 (28.1) .991
Started tuberculosis treatment 50 (56.2) 7 (28.0) 43 (67.2) .001
Started ART and tuberculosis treatment 14 (15.7) 1 (4.0) 13 (20.3) .101
Started ART before starting tuberculosis treatment 13 (14.6) 7 (28.0) 6 (9.4) .025
Transferred out 0 0 0 .
Lost to follow-up 9 (10.1) 4 (16.0) 5 (7.8) .261
Death 6 (6.7) 0 6 (9.4) .179
Alive and in program 74 (83.2) 21 (84.0) 53 (82.8) 1
90-day follow-up
Started ART 57 (64.0) 18 (72.0) 39 (60.9) .328
Started tuberculosis treatment 66 (74.2) 17 (68.0) 49 (76.6) .407
Started ART and tuberculosis treatment 48 (53.9) 13 (52.0) 35 (54.7) .819
Started ART before starting tuberculosis treatment 18 (20.2) 11 (44.0) 7 (10.9) ,.001
Transferred out 1 (1.1) 0 1 (1.6) 1
Unavailable for follow-up 12 (13.5) 4 (16.0) 8 (12.5) .733
Death 6 (6.7) 0 6 (9.4) .179
Alive and in program 70 (78.7) 21 (84.0) 49 (76.6) .570
Timing of treatment
a
Time to starting ART, median (IQR), days 32 (27–48) 37.5 (28–62) 31 (27–48) .4187
Time to starting tuberculosis treatment, median (IQR), days 14 (8–30) 32 (26–48) 9 (6–18) ,.0001
Variables are numbers (%) unless otherwise stated.
Abbreviations: ART, antiretroviral therapy; IQR, interquartile range.
a Based on patients who started treatment within 90 days of follow-up.
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